Healthcare -
Medical - Healthcare Information Services - NASDAQ - US
$ 84.74
-0.306 %
$ 38.7 B
Market Cap
23.22
P/E
1. INTRINSIC VALUE
Balance Sheet
GE HealthCare Technologies Inc.
| Current Assets | 9.41 B |
| Cash & Short-Term Investments | 2.49 B |
| Receivables | 4.25 B |
| Other Current Assets | 2.66 B |
| Non-Current Assets | 23 B |
| Long-Term Investments | 357 M |
| PP&E | 2.5 B |
| Other Non-Current Assets | 20.2 B |
| Current Liabilities | 8.98 B |
| Accounts Payable | 2.95 B |
| Short-Term Debt | 1.12 B |
| Other Current Liabilities | 4.92 B |
| Non-Current Liabilities | 16.2 B |
| Long-Term Debt | 8.75 B |
| Other Non-Current Liabilities | 7.42 B |
EFFICIENCY
Earnings Waterfall
GE HealthCare Technologies Inc.
| Revenue | 19.6 B |
| Cost Of Revenue | 11.6 B |
| Gross Profit | 7.92 B |
| Operating Expenses | 5.49 B |
| Operating Income | 2.44 B |
| Other Expenses | 867 M |
| Net Income | 1.57 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
GE HealthCare Technologies Inc.
| Net Income | 1.57 B |
| Depreciation & Amortization | 610 M |
| Capital Expenditures | -387 M |
| Stock-Based Compensation | 114 M |
| Change in Working Capital | -131 M |
| Others | -847 M |
| Free Cash Flow | 1.71 B |
Wall Street Analysts Price Targets
GE HealthCare Technologies Inc.
Wall Street analysts predict an average 1-year price target for GEHC of $96 , with forecasts ranging from
a
low of
$74 to a high of $110 .
GEHC Lowest Price Target
Wall Street Target
74 USD
-12.67%
GEHC Average Price Target
Wall Street Target
96 USD
13.29%
GEHC Highest Price Target
Wall Street Target
110 USD
29.81%
4. DIVIDEND
ANALYSIS
0.03%
DIVIDEND YIELD
0.035 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
GE HealthCare Technologies Inc.
Sold
0-3 MONTHS
388 K USD 2
3-6 MONTHS
1.8 M USD 2
6-9 MONTHS
7.37 M USD 2
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
101 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 months ago
Nov 06, 2024
|
Sell 309 K
USD
|
Rott Roland
CEO, Imaging
|
- 3577
|
86.48 USD |
|
2 months ago
Nov 05, 2024
|
Sell 78.9 K
USD
|
Rackliffe Philip
CEO, AVS
|
- 900
|
87.63 USD |
|
5 months ago
Aug 14, 2024
|
Sell 1.58 M
USD
|
Stacherski Kenneth R.
Ch. Supply Chain & Serv. Ofc.
|
- 19008
|
83.22 USD |
|
5 months ago
Aug 07, 2024
|
Sell 222 K
USD
|
Westrick Thomas J.
CEO, Patient Care Solutions
|
- 2750
|
80.78 USD |
|
7 months ago
May 28, 2024
|
Sell 260 K
USD
|
Kass-Hout Taha
Chief Technology Officer
|
- 3300
|
78.7 USD |
|
8 months ago
May 13, 2024
|
Sell 1.65 M
USD
|
Makela Jan
CEO, Imaging
|
- 20227
|
81.57 USD |
|
8 months ago
May 15, 2024
|
Sell 5.46 M
USD
|
Makela Jan
CEO, Imaging
|
- 66955
|
81.54 USD |
|
8 months ago
May 01, 2024
|
Bought
101 K USD
|
Jimenez Frank R
GC & Corporate Secretary
|
+ 1315
|
76.52 USD |
|
1 year ago
Jul 31, 2023
|
Sell 179 K
USD
|
O'Neill Kevin Michael
CEO, PDx
|
- 2334
|
76.55 USD |
|
1 year ago
Jul 31, 2023
|
Sell 1.03 M
USD
|
O'Neill Kevin Michael
CEO, PDx
|
- 13275
|
77.46 USD |
|
1 year ago
Jun 08, 2023
|
Sell 191 K
USD
|
Rott Roland
CEO, Ultrasound
|
- 2473
|
77.37 USD |
|
1 year ago
Jan 23, 2023
|
Bought
51.8 K USD
|
CULP H LAWRENCE JR
Director
|
+ 748
|
69.26 USD |
|
1 year ago
Mar 14, 2023
|
Sell 5.04 M
USD
|
Makela Jan
CEO, Imaging
|
- 64945
|
77.66 USD |
|
1 year ago
Mar 14, 2023
|
Sell 444 K
USD
|
Makela Jan
CEO, Imaging
|
- 5684
|
78.07 USD |
7. News
Why GE HealthCare Technologies (GEHC) is a Top Stock for the Long-Term
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
zacks.com
- 1 week ago
United States External Cardiology Remote Monitors Market Outlook to 2033 Featuring Key Players, GE HealthCare, Shenzhen Mindray Bio-Medical Electronics, and Nihon Kohden
Dublin, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The "United States External Cardiology Remote Monitors Market Outlook to 2033" report has been added to ResearchAndMarkets.com's offering. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - External Cardiology Remote Monitors
globenewswire.com
- 2 weeks ago
GEHC vs. PODD: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Products sector have probably already heard of GE HealthCare Technologies (GEHC) and Insulet (PODD). But which of these two companies is the best option for those looking for undervalued stocks?
zacks.com
- 2 weeks ago
5 Top AI-in-MedTech Stocks for Big Gains in 2025: MDT, BSX & More
Here we discuss five medical stocks - MDT, BSX, BDX, GEHC and TEM - incorporating AI in their workflows. These are likely to gain in 2025 as AI helps cut costs and improve patient care.
zacks.com
- 2 weeks ago
Why GE HealthCare Technologies (GEHC) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
- 3 weeks ago
2025 Could Be GE HealthCare's Year With Emphasis On Efficiency And AI Broadens
GE HealthCare shares have surged nearly 27% since October 2023, driven by AI-driven strategies and innovation in healthcare diagnostics, despite some volatility in revenue growth. The bullish outlook for 2025 is supported by GEHC's AI advancements, expected sales and profitability improvements, and a significant backlog of $19.6 billion. AI-driven healthcare solutions are projected to enhance diagnostic accuracy, reduce treatment costs, and drive market growth, with GEHC positioned as a leader with numerous FDA-approved devices.
seekingalpha.com
- 1 month ago
Reasons to Retain GE HealthCare Stock in Your Portfolio Now
GEHC's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
zacks.com
- 1 month ago
GE HealthCare: Growth Acceleration In 2025 Can Drive Stock Higher
GE HealthCare Technologies is rated a buy due to strong growth prospects, a healthy backlog, and favorable valuation compared to peers. The company's revenue growth is supported by new product innovations, including the FDA-approved Flyrcado, and potential recovery in Chinese demand. Margins are expected to improve through cost optimization, volume leverage, and strategic pricing, with a medium-term EBIT margin target of high teens to 20%.
seekingalpha.com
- 1 month ago
GEHC Stock May Gain Following the Launches of Aurora and Clarify DL
GE HealthCare announces that Aurora will expand the range of CT procedures and Clarify DL will enhance SPECT image quality.
zacks.com
- 1 month ago
GE HealthCare Expands Its Effortless Recon DL Portfolio, Bringing Advanced Deep Learning Image Reconstruction to Clinicians Worldwide
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) unveiled three new advanced deep learning image processing and reconstruction solutions as a part of its Effortless Recon DL portfolio at the Radiological Society of North America (RSNA) 2024 Annual Meeting, in Chicago, IL. Understanding the need to improve operational efficiencies within radiology departments and the ongoing challenge of burnout experienced by clinicians, GE HealthCare developed the technologies to deliver exceptional imag.
businesswire.com
- 1 month ago
GEHC Stock May Gain From Potential FDA Clearance for CleaRecon DL
GE HealthCare announces the FDA submission of its CleaRecon DL technology to improve CBCT images.
zacks.com
- 1 month ago
GE HealthCare showcases commitment to sustainable innovation at RSNA 2024
CHICAGO--(BUSINESS WIRE)--As part of a companywide commitment to advance innovation that improves the health of patients and the planet, GE HealthCare (Nasdaq: GEHC) is highlighting several solutions with increased focus on sustainability at the Radiological Society of North America (RSNA) 2024 Annual Meeting, which is held Dec. 1-4 in Chicago, IL. “With a deep appreciation for the importance of sustainability, at GE HealthCare, we are managing our environmental footprint by integrating sustain.
businesswire.com
- 1 month ago
8. Profile
Summary
GE HealthCare Technologies Inc. GEHC
COUNTRY
US
INDUSTRY
Medical - Healthcare Information Services
MARKET CAP
$ 38.7 B
Dividend Yield
0.03%
Description
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Contact
500 West Monroe Street, Chicago, IL, 60661
https://www.gehealthcare.com
IPO
Date
Dec. 15, 2022
Employees
51000
Officers
Ms. Rana Strellis
Chief Corporate Marketing & Communications Officer
Mr. Frank R. Jimenez Esq.
Vice President, General Counsel & Corporate Secretary
Mr. Adam Holton
Chief People Officer
Dr. Taha Kass-Hout M.D., M.S.
Chief Science & Technology Officer
Mr. Jahid Khandaker
Chief Information Officer
Mr. Thomas J. Westrick
President & Chief Executive Officer of Patient Care Solutions
Mr. James K. Saccaro
Vice President & Chief Financial Officer
Mr. Peter J. Arduini
President, Chief Executive Officer & Director
Mr. George Andrew Newcomb
Controller & Chief Accounting Officer
Ms. Carolynne Borders
Chief Investor Relations Officer